Incyte discontinues Jakafi trials in solid tumors
Incyte Corp. (NASDAQ:INCY) reported 4Q15 and 2015 revenues that beat expectations but fell $6.80 to $65.51 on Thursday after it said it would discontinue all ongoing trials of myelofibrosis drug Jakafi ruxolitinib in solid tumors, including the Phase III JANUS 1 and JANUS 2 trials of Jakafi plus Xeloda capecitabine as a second-line therapy for advanced or metastatic pancreatic cancer.
The biotech said a planned interim analysis of JANUS 1 "did not show a sufficient level of efficacy to warrant continuation," following a similar outcome in metastatic colorectal cancer (mCRC). Last month, Incyte said it would stop early a substudy of a Phase II trial of Jakafi plus Stivarga regorafenib for mCRC after a planned interim analysis. Incyte will now discontinue that entire Phase II study (see BioCentury Extra, Jan. 27). ...